Literature DB >> 25189649

The interrelationship between HER2 and CASP3/8 with apoptosis in different cancer cell lines.

Kaifee Arman1, Sercan Ergün, Ebru Temiz, Serdar Öztuzcu.   

Abstract

HER2/ErbB2, a known proto-oncogene (also known as HER2, neu), is among the most practiced molecules in the cancer area. Human epidermal growth factor receptor 2 (HER2) is over expressed in approximately 20-30 % of breast cancer tumors and also in a lot of other human cancer types. It is known to be related to the aggressiveness of the disease, increased mortality and higher relapse ratio. The unusual HER2 overexpression is associated with more severe disease characteristics in several cancers. In recent past, there have been remarkable advances in understanding the role of the HER2 gene in cancers. Caspases are well renowned proteases that act as essential initiators and executioners of the apoptotic process. The primary function of HER2 is suppressing apoptosis to enhance cell survival and eventually giving rise to uncontrolled proliferation and tumor growth. The objective of this work was to study the expression levels of HER2 and apoptosis related factors CASP-3 and CASP-8 in several breast and other cancer cell lines and finally to find a meaningful correlation between all these. We summed up by obtaining an increase in expression of HER2 in all cancer cell lines as compared to that of CASP-3 and CASP-8. In summary we conclude that HER2 promotes cell survival by inhibiting apoptosis i.e. by downregulating CASP-3 and CASP-8. This is a novel study comprising the expression study of HER2 and different caspases in different cancer cell lines simultaneously. It is thus expected that this study will aid in better establishment of correlation between HER2 and caspases in different malignancies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25189649     DOI: 10.1007/s11033-014-3700-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  40 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  Regulation of Apoptosis by HER2 in Breast Cancer.

Authors:  Richard L Carpenter; Hui-Wen Lo
Journal:  J Carcinog Mutagen       Date:  2013-06-26

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

4.  The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.

Authors:  M D Pegram; R S Finn; K Arzoo; M Beryt; R J Pietras; D J Slamon
Journal:  Oncogene       Date:  1997-07-31       Impact factor: 9.867

5.  The prognostic value of HER-2/neu oncogene in cervical cancer.

Authors:  B Ndubisi; S Sanz; L Lu; E Podczaski; G Benrubi; S Masood
Journal:  Ann Clin Lab Sci       Date:  1997 Nov-Dec       Impact factor: 1.256

6.  [Expression of HER-2/neu oncogene in hepatocellular carcinoma and the clinical implications].

Authors:  Jun-kai Zhang; Pei-ling Pan; Ying-meng Wu; Jian-jun Xiao; Jie-wen Peng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2010-02

7.  Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein.

Authors:  De-Xin Zhang; Peng-Tao Zhao; Lin Xia; Li-Li Liu; Jie Liang; Hui-Hong Zhai; Hong-Bo Zhang; Xue-Gang Guo; Kai-Chun Wu; Yan-Ming Xu; Lin-Tao Jia; An-Gang Yang; Si-Yi Chen; Dai-Ming Fan
Journal:  Gut       Date:  2009-11-30       Impact factor: 23.059

8.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

9.  Expression patterns of miR-221 and its target Caspase-3 in different cancer cell lines.

Authors:  Sercan Ergun; Kaifee Arman; Ebru Temiz; Ibrahim Bozgeyik; Önder Yumrutaş; Muhammad Safdar; Hasan Dağlı; Ahmet Arslan; Serdar Oztuzcu
Journal:  Mol Biol Rep       Date:  2014-06-27       Impact factor: 2.316

Review 10.  Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.

Authors:  Stephen G Ward; Peter Finan
Journal:  Curr Opin Pharmacol       Date:  2003-08       Impact factor: 5.547

View more
  5 in total

Review 1.  Oncocers: ceRNA-mediated cross-talk by sponging miRNAs in oncogenic pathways.

Authors:  Sercan Ergun; Serdar Oztuzcu
Journal:  Tumour Biol       Date:  2015-03-27

2.  Detection of HER2 polymorphism and expression using circulating DNA and RNA as a tool in lung adenocarcinoma patients: a case control study.

Authors:  Masroor Mirza; Jamsheed Javid; Prasant Yadav; Anant Mohan; Prakash Chandra Ray; Alpana Saxena
Journal:  Ann Transl Med       Date:  2016-06

3.  Identification of a Water-Coordinating HER2 Inhibitor by Virtual Screening Using Similarity-Based Scoring.

Authors:  Jiaye Guo; Stephen Collins; W Todd Miller; Robert C Rizzo
Journal:  Biochemistry       Date:  2018-07-30       Impact factor: 3.162

4.  Identification of core differentially methylated genes in glioma.

Authors:  Jing Xue; Hai-Xia Gao; Wei Sang; Wen-Li Cui; Ming Liu; Yan Zhao; Meng-Bo Wang; Qian Wang; Wei Zhang
Journal:  Oncol Lett       Date:  2019-10-02       Impact factor: 2.967

5.  Telomerase as a Possible Candidate Targeting Therapy in Different Breast Cancer Cell Lines.

Authors:  Salma Aboelela; Abeer Ashmawy; Sabry Shaarawy; Mohammed El-Hefny; Amina Medhat
Journal:  Asian Pac J Cancer Prev       Date:  2020-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.